Lornoxicam: A Comprehensive Pharmacological Review

1. Introduction to Lornoxicam

Overview and Therapeutic Significance

Lornoxicam, also known by its chemical name chlortenoxicam, is a potent non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class of therapeutic agents.[1] It is well-recognized for its pronounced analgesic, anti-inflammatory, and antipyretic properties.[1] The primary clinical applications of lornoxicam include the management of acute mild to moderate pain, as well as the symptomatic relief of pain and inflammation associated with a spectrum of rheumatic conditions, most notably osteoarthritis and rheumatoid arthritis.[1]

A key distinguishing characteristic of lornoxicam, when compared with other members of the oxicam family, is its potent inhibition of prostaglandin biosynthesis. This potent action is coupled with a relatively short plasma elimination half-life, typically observed to be between 3 to 5 hours.[1] This pharmacokinetic profile is of particular interest as it is suggested to contribute to a potentially more favorable gastrointestinal (GI) tolerability profile. The rationale behind this improved tolerability lies in the reduced likelihood of drug accumulation and less sustained inhibition of cyclooxygenase-1 (COX-1) in the gastrointestinal mucosa, an enzyme crucial for maintaining gastric mucosal integrity.

The development of lornoxicam, characterized by this specific combination of high potency and a short elimination half-life, appears to reflect a strategic pharmacological objective. This strategy aims to harness the robust therapeutic efficacy typical of the oxicam class while concurrently seeking to minimize the cumulative GI toxicity that is often associated with NSAIDs possessing longer elimination half-lives. Oxicams as a class are renowned for their strong anti-inflammatory effects; however, this efficacy is often counterbalanced by a significant risk of GI adverse events. This risk is, in part, attributed to their typically long elimination half-lives, which lead to prolonged inhibition of COX-1 in the GI mucosa. Lornoxicam's potent inhibition of prostaglandin synthesis ensures a substantial anti-inflammatory and analgesic action.[1] Its comparatively short half-life of 3-5 hours [22] represents a deliberate divergence from other oxicams, such as piroxicam, which has a half-life of approximately 50 hours.[27] This shorter duration of action is theorized to diminish the continuous insult to the GI lining, potentially translating to better GI tolerability.[23] Consequently, lornoxicam can be viewed as a pharmacological endeavor to optimize the benefit-risk ratio within the oxicam class, targeting high efficacy with a reduced window for the manifestation of mechanism-based side effects.

Development and International Availability

Lornoxicam was first patented in 1977, with its initial approval for medical use following in 1997.[11] It has secured regulatory approval in Japan [1] and is currently marketed under various brand names (e.g., Xefo, Lorcam) in a multitude of countries spanning Europe, the Middle East, the Far East, and South America.[13] This widespread availability underscores its established role in pain and inflammation management globally. The drug's characteristics and market presence highlight the ongoing clinical demand for effective NSAIDs that also offer improved safety profiles. The development pathway of lornoxicam is illustrative of the persistent pharmaceutical challenge: to effectively dissociate potent anti-inflammatory and analgesic activity from the mechanism-based toxicities, particularly the GI and cardiovascular risks that are inherent to the inhibition of cyclooxygenase enzymes.

2. Chemical and Physicochemical Properties

A thorough understanding of lornoxicam's chemical and physicochemical characteristics is essential for comprehending its pharmacological behavior, guiding formulation strategies, and ensuring its safe and effective use.

Chemical Identity

Lornoxicam is chemically identified as:

• IUPAC Name: 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide [1] or, with slightly different nomenclature, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide-1,1-dioxide.[2]
• Synonyms: Commonly used synonyms include chlortenoxicam, Ro 13-9297, and TS 110.[2]
• Chemical Class: Lornoxicam is classified as an oxicam and is a thienothiazine derivative.[1]

Molecular Structure

Lornoxicam is a thienothiazine-derived monocarboxylic acid amide. Its structure arises from the formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine.33

Key structural representations include:

• SMILES (Simplified Molecular Input Line Entry System): CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3.[1]
• InChIKey (International Chemical Identifier Key): WLHQHAUOOXYABV-UHFFFAOYSA-N.[1] The molecular architecture features the characteristic enol-type acidic proton of the oxicam class, a thienothiazine heterocyclic system, and a pyridine moiety, all contributing to its pharmacological activity and physicochemical properties.

Identifiers and Physical State

• Molecular Formula: C₁₃H₁₀ClN₃O₄S₂.[1]
• Molecular Weight: Approximately 371.8 g/mol. Various sources report values ranging from 371.8 g/mol to 371.82 g/mol.[1]
• CAS Number: 70374-39-9.[1]
• DrugBank ID: DB06725.[1]
• Appearance: Lornoxicam is described as a crystalline solid.[2] Its color can range from light orange to yellow or even green as a powder or crystal.[7]

Solubility and Related Properties

The solubility characteristics of lornoxicam are crucial for its absorption and formulation:

• Solubility in Organic Solvents: It is soluble in common organic solvents, including ethanol (approximately 1 mg/mL), dimethyl sulfoxide [2], and dimethylformamide (DMF, approximately 1 mg/mL).[2]
• Aqueous Solubility: Lornoxicam is reported to be soluble in water at a concentration of 1 mg/mL; however, aqueous solutions are not recommended for storage beyond one day due to potential stability issues.[2]
• pH-Dependent Solubility: Being a weak acid, lornoxicam's aqueous solubility is markedly pH-dependent. Its solubility increases exponentially as the pH rises from 3.0 to 9.0.[12] This property is critical for its dissolution in different segments of the gastrointestinal tract. In the acidic environment of the stomach (pH 1-2), lornoxicam, with a pKa of 4.7, will exist predominantly in its un-ionized, less water-soluble form. Conversely, in the more neutral or slightly alkaline pH of the small intestine (pH 6-7.4), the proportion of the ionized, more water-soluble form increases, thereby enhancing its dissolution.[12] Slow or incomplete dissolution can significantly delay absorption and the onset of action, which is particularly undesirable for an analgesic medication. This inherent characteristic explains the pharmaceutical focus on developing formulations designed to overcome this limitation, such as "quick-release" tablets [12] or formulations that incorporate alkaline agents to create a local microenvironment with a higher pH, thereby accelerating the dissolution process.[12]
• pKa: The acidity constant (pKa) of lornoxicam is 4.7.[12]
• Melting Point: Lornoxicam melts with decomposition at a range of 225-230°C [32] or 229-231°C.[7]
• Log P (Partition Coefficient): The n-octanol/pH 7.4 buffer partition coefficient is 1.8 [32], indicating moderate lipophilicity.
• UV/Vis Absorption Maxima (λ_max): Lornoxicam exhibits characteristic UV/Vis absorption maxima at 270 nm and 381 nm.[2] Another source reports a λ_max at 371 nm.[32]

Crystal Structure

Detailed crystallographic data for lornoxicam are available, including Crystallography Open Database (COD) numbers and space group information (e.g., Hermann-Mauguin space group symbol P 21 21 21).[1] This indicates a well-characterized solid-state structure, which is fundamental for understanding solid-state properties, identifying potential polymorphs, and for advanced pharmaceutical formulation design.

The challenge of formulating a poorly soluble weak acid like lornoxicam for rapid and consistent oral absorption is a common consideration in pharmaceutical sciences. The strategies employed, such as the use of alkaline excipients or the investigation of cyclodextrin inclusion complexes [12], reflect broader industry approaches to enhance the bioavailability and therapeutic utility of such drug candidates. This also underscores the value of parenteral formulations [7] as alternatives when rapid onset and complete systemic availability are paramount.

Table 1: Physicochemical Properties of Lornoxicam

Property	Value	Reference(s)
IUPAC Name	6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide	1
Molecular Formula	C<sub>13</sub>H<sub>10</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub>	1
Molecular Weight	~371.8 g/mol	1
CAS Number	70374-39-9	1
DrugBank ID	DB06725	1
Appearance	Crystalline solid; light orange to yellow to green powder/crystal	2
Solubility (Water)	1 mg/mL (pH-dependent; unstable beyond 1 day)	2
Solubility (Ethanol)	~1 mg/mL	2
Solubility (DMSO)	~2 mg/mL 2; >5 mg/mL (warmed) 34	2
Solubility (DMF)	~1 mg/mL	2
pKa	4.7	12
Melting Point	225-230°C (dec.) or 229-231°C (dec.)	7
Log P (n-octanol/pH 7.4)	1.8	32
UV/Vis λ<sub>max</sub>	270 nm, 381 nm (or 371 nm)	2

3. Mechanism of Action and Pharmacodynamics

Primary Mechanism: Cyclooxygenase (COX) Inhibition

Lornoxicam exerts its primary therapeutic effects—analgesia, anti-inflammation, and antipyresis—through the potent inhibition of cyclooxygenase (COX) enzymes.[1] COX enzymes, existing as two main isoforms, COX-1 and COX-2, are critical for the biosynthesis of prostaglandins and thromboxanes from their precursor, arachidonic acid. By inhibiting these enzymes, lornoxicam effectively curtails the production of these eicosanoids, which are pivotal mediators of inflammation, pain sensitization, and fever.[1]

COX Isoform Selectivity and Potency

Lornoxicam is characterized by a balanced inhibitory profile against both COX-1 and COX-2 isoforms.[3] In vitro studies have quantified this potency, with reported IC₅₀ values (the concentration required to inhibit enzyme activity by 50%) of approximately 3 nM for COX-1 (assessed by inhibition of thromboxane B2 production in human erythroleukemic cells) and 8 nM for COX-2 (assessed by inhibition of prostaglandin F_1α formation in Mono-Mac-6 cells).[2] These low nanomolar IC₅₀ values underscore the high potency of lornoxicam against both cyclooxygenase isoforms. The similar magnitude of these values confirms its non-selective nature, meaning it does not preferentially inhibit one isoform over the other. This balanced, potent inhibition is a double-edged sword: while ensuring robust analgesic and anti-inflammatory effects (largely attributed to COX-2 inhibition), it inherently carries the risk of mechanism-based side effects, particularly gastrointestinal toxicity, due to the concurrent potent inhibition of the constitutively expressed COX-1 enzyme. Even though lornoxicam's short half-life is intended to mitigate some of these risks, the fundamental mechanism of potent COX-1 inhibition remains, explaining why GI adverse events are commonly reported.[3]

Additional Pharmacodynamic Effects

Beyond its primary action on COX enzymes, lornoxicam may exhibit other pharmacodynamic effects that contribute to its overall therapeutic profile:

• Leukotriene Pathway Modulation: It has been reported that, unlike some other NSAIDs, lornoxicam's inhibition of cyclooxygenase does not lead to a significant increase in the formation of leukotrienes.[4] This suggests that the metabolic shunting of arachidonic acid from the COX pathway to the 5-lipoxygenase pathway (which produces leukotrienes) may be minimal with lornoxicam. This characteristic could be clinically relevant. Arachidonic acid serves as a common precursor for both prostaglandins (via COX enzymes) and leukotrienes (via 5-lipoxygenase). If the COX pathway is substantially blocked, there is a potential for substrate (arachidonic acid) to be shunted towards the 5-lipoxygenase pathway, leading to increased production of leukotrienes. Elevated levels of leukotrienes are implicated in the pathophysiology of certain conditions, such as bronchoconstriction and other hypersensitivity reactions, particularly in susceptible individuals (e.g., those with aspirin-exacerbated respiratory disease, AERD). If lornoxicam indeed avoids or minimizes this metabolic shunting, as suggested by some sources [4], it might offer a theoretical safety advantage in patients prone to leukotriene-mediated adverse reactions. However, this potential benefit would need to be carefully weighed against the risks associated with its COX-1 inhibitory activity.
• Central Analgesic Mechanisms: There is some evidence to suggest that lornoxicam may also exert analgesic effects through central nervous system mechanisms, possibly by modulating endogenous opioid pathways, such as increasing the levels of dinorphin and beta-endorphin.[10]
• Anti-inflammatory Cellular Effects: Lornoxicam has been shown to inhibit the migration of polymorphonuclear (PMN) leukocytes and to reduce the release of superoxide radicals from these cells.[10] Furthermore, it can inhibit the release of platelet-derived growth factor (PDGF) from human platelets and has been observed to stimulate the synthesis of proteoglycans in cartilage in tissue culture models.[10]
• Inhibition of Other Inflammatory Mediators: In cell-based assays, lornoxicam has demonstrated the ability to reduce lipopolysaccharide (LPS)-induced production of nitric oxide (NO) and the pro-inflammatory cytokine Interleukin-6 (IL-6), with reported IC₅₀ values of 65 µM and 54 µM, respectively.[2]

The inhibition of iNOS and IL-6 formation, along with effects on PMN leukocyte migration, suggests that lornoxicam's anti-inflammatory actions might be broader than just prostaglandin synthesis inhibition. These additional effects could contribute to its overall efficacy, particularly in complex inflammatory states, even if these effects occur at higher concentrations than those required for COX inhibition.

Comparative Potency

In vitro, lornoxicam has been reported to be approximately 100-fold more potent than tenoxicam in inhibiting prostaglandin D₂ (PGD₂) formation in rat polymorphonuclear leukocytes.[10] Clinical comparisons also indicate high efficacy relative to other NSAIDs and even some opioid analgesics in specific pain models.

4. Pharmacokinetics (ADME)

The pharmacokinetic profile of lornoxicam, encompassing its absorption, distribution, metabolism, and excretion (ADME), is crucial for understanding its clinical use, dosing regimens, and potential for variability in patient response.

Absorption

Lornoxicam is characterized by rapid and nearly complete absorption from the gastrointestinal tract following oral administration.

• Bioavailability: The oral bioavailability of lornoxicam is high, reported to be in the range of 90-100%.[4]
• Time to Peak Plasma Concentration (T_max): After oral administration, peak plasma concentrations (C_max) are typically achieved within 1 to 2 hours [39] or up to 2.5 hours.[26] For instance, a 4 mg oral dose of lornoxicam results in a C_max of 280 µg/L within approximately 2.5 hours.[26] Intramuscular injection leads to a more rapid attainment of C_max, generally within 20-25 minutes [26], with an absolute bioavailability of 97% via this route.[26]
• Effect of Food: The presence of food in the stomach can influence the absorption of lornoxicam. Concurrent food intake typically delays the rate of absorption, increasing T_max from approximately 1.5 hours to 2.3 hours, and may slightly reduce the extent of absorption, with the area under the plasma concentration-time curve (AUC) potentially decreasing by about 15-20%.[26]
• First-Pass Metabolism: Lornoxicam does not appear to undergo significant first-pass hepatic metabolism.[39] The rapid absorption and high bioavailability contribute significantly to lornoxicam's utility, particularly in acute pain scenarios where a quick onset of action is desired. The observed food effect suggests that for the most rapid onset, administration on an empty stomach may be preferable.

Distribution

Once absorbed, lornoxicam distributes within the body as follows:

• Plasma Protein Binding: Lornoxicam is highly bound to plasma proteins, with approximately 99% of the drug bound, almost exclusively to serum albumin.[1] This high degree of protein binding can have implications for drug interactions (e.g., displacement by or of other highly bound drugs) and influences the concentration of free, pharmacologically active drug.
• Volume of Distribution (V_d): The apparent volume of distribution of lornoxicam is low, reported as 0.14 L/kg [40] or 0.3 L/kg.[26] This low V_d is consistent with its extensive plasma protein binding, which tends to restrict the drug's distribution into tissues.
• Synovial Fluid Penetration: Despite its high protein binding, lornoxicam has been shown to achieve substantial concentrations in synovial fluid.[22] This is clinically relevant as synovial fluid is the proposed site of action for NSAIDs in the treatment of inflammatory joint diseases like osteoarthritis and rheumatoid arthritis.

Metabolism

Lornoxicam undergoes extensive and complete metabolism, primarily in the liver.[4]

• Primary Metabolic Pathway and Enzyme: The principal metabolic pathway for lornoxicam is 5'-hydroxylation, which is predominantly catalyzed by the cytochrome P450 isoenzyme CYP2C9.[4] This specific metabolic route accounts for as much as 95% of the total intrinsic clearance of lornoxicam.[25]
• Major Metabolite: The primary product of this hydroxylation is 5'-hydroxy-lornoxicam, which is pharmacologically inactive.[4]
• Influence of CYP2C9 Genetic Polymorphisms: The pharmacokinetics of lornoxicam are subject to significant interindividual variability, largely attributable to genetic polymorphisms in the CYP2C9 gene.[25]
• Individuals carrying variant CYP2C9 alleles associated with reduced enzyme activity, such as CYP2C9*2 and CYP2C9*3, exhibit impaired oral clearance and consequently increased systemic exposure to lornoxicam. For example, studies have shown that individuals heterozygous for the CYP2C9*1 allele (e.g., CYP2C9*1/*3 genotype) can have approximately a 2-fold increase in AUC and a 55% reduction in clearance compared to individuals homozygous for the wild-type CYP2C9*1/*1 allele.[25]
• In rare instances, individuals who are very poor metabolizers of CYP2C9 substrates (e.g., those homozygous or compound heterozygous for deficient alleles) can experience a dramatic prolongation of lornoxicam's elimination half-life (e.g., from the typical 3-5 hours to over 100 hours) and a substantial increase in overall drug exposure, heightening the risk of adverse effects.[25] The heavy reliance on CYP2C9 for metabolism means that individuals with reduced CYP2C9 activity will experience significantly prolonged half-life and increased exposure, potentially negating the safety advantage of the short half-life and increasing the risk of dose-dependent adverse effects.
• Furthermore, physiologically based pharmacokinetic (PBPK) modeling studies suggest that liver cirrhosis can also significantly increase lornoxicam exposure, with the impact potentially being more pronounced than that of CYP2C9 genotype alone, depending on the severity of the liver impairment.[41] The profound influence of CYP2C9 genetic status on lornoxicam's pharmacokinetics underscores the potential for marked differences in drug response and tolerability among patients. This variability suggests that a standard dosing regimen may not be optimal for all individuals, pointing towards the potential clinical utility of pharmacogenetic testing or more cautious dose titration, particularly in populations with a known high prevalence of CYP2C9 variants or in patients who exhibit an unexpected response or adverse effects.

Excretion

Lornoxicam is eliminated from the body primarily in the form of its metabolites.

• Only negligible amounts of the parent drug are excreted unchanged in the urine.[4]
• The elimination routes are both hepatic and renal. Approximately two-thirds of the administered dose (reported as 50-51%) are eliminated via the liver (with metabolites excreted in the faeces through biliary pathways), and about one-third (reported as 42%) is excreted via the kidneys, mainly as 5'-hydroxy-lornoxicam and its glucuronide conjugate.[4]
• The metabolites of lornoxicam do not appear to undergo significant enterohepatic recirculation.[22]

Elimination Half-Life (t_1/2)

A key pharmacokinetic feature of lornoxicam is its relatively short elimination half-life.

• Parent Drug: In individuals with normal CYP2C9 function, the elimination half-life of lornoxicam typically ranges from 3 to 5 hours.[3] This characteristic contributes to its suitability for acute pain management, allowing for a relatively rapid onset of action and potentially reducing the risk of accumulation-related side effects often seen with longer-acting NSAIDs. However, this benefit can be significantly compromised in individuals who are poor metabolizers via CYP2C9.
• Metabolite: The inactive 5'-hydroxy-lornoxicam metabolite has a longer elimination half-life, reported to be approximately 9 to 11 hours.[22]

The pharmacokinetic profile, especially the rapid absorption and short elimination half-life, underpins lornoxicam's clinical utility for acute pain. However, the substantial interindividual variability due to CYP2C9 polymorphisms necessitates careful consideration in clinical practice. For optimal and safe use, particularly in the context of chronic conditions or in patients with potential risk factors, an understanding of an individual's metabolic capacity for lornoxicam could be highly beneficial, aligning with the broader principles of personalized medicine.

Table 2: Key Pharmacokinetic Parameters of Lornoxicam

Parameter	Value	Reference(s)
Bioavailability (Oral)	90-100%	4
Bioavailability (IM)	97%	26
T<sub>max</sub> (Oral, fasted)	1-2.5 hours	26
T<sub>max</sub> (Oral, with food)	~2.3 hours (delayed)	26
T<sub>max</sub> (IM)	~20-25 minutes	26
C<sub>max</sub> (Oral, with food)	Reduced (AUC decreased by ~15-20%)	26
Volume of Distribution (V<sub>d</sub>)	0.14 - 0.3 L/kg	26
Plasma Protein Binding	99% (primarily to albumin)	1
Elimination Half-life (Lornoxicam)	3-5 hours (normal metabolizers)	4
Elimination Half-life (5'-OH-Lornoxicam)	~9-11 hours	22
Primary Metabolic Pathway	5'-Hydroxylation	4
Key Metabolizing Enzyme	CYP2C9	4
Major Metabolite	5'-hydroxy-lornoxicam (inactive)	4
Routes of Excretion	~67% Hepatic (faeces), ~33% Renal (urine, as metabolites)	4
Impact of CYP2C9 Polymorphisms	Significant variability; poor metabolizers show markedly increased t<sub>1/2</sub> and AUC	25

5. Therapeutic Indications and Clinical Efficacy

Lornoxicam is indicated for a range of painful and inflammatory conditions, leveraging its potent analgesic and anti-inflammatory properties.

Approved and Common Indications

The primary therapeutic uses of lornoxicam include:

• Treatment of acute mild to moderate pain: This is a broad indication covering various pain types.[1]
• Symptomatic relief of pain and inflammation in osteoarthritis: Lornoxicam is used to manage the chronic pain and inflammation associated with this degenerative joint disease.[1]
• Symptomatic relief of pain and inflammation in rheumatoid arthritis: It is also employed in the management of this autoimmune inflammatory arthritis.[1]
• Pain associated with sciatica, acute lumbar-sciatica conditions, and low back pain: These musculoskeletal conditions are common targets for lornoxicam therapy.[1]
• Postoperative pain management: Lornoxicam is widely used for pain relief after various surgical procedures, including oral/dental surgery [12], gynaecological surgery, and orthopaedic surgery.[2]
• Ankylosing spondylitis: This chronic inflammatory disease affecting the spine is another indication for lornoxicam.[6]

Summary of Clinical Efficacy

Clinical trials have demonstrated the efficacy of lornoxicam across its indicated uses:

• Postoperative Pain:
• Lornoxicam, particularly at doses of 8 mg or higher, has shown efficacy comparable to or greater than other NSAIDs and even some opioid analgesics in the context of postoperative pain. For instance, after oral surgery, it was found to be at least as effective as comparative NSAIDs and more effective than 10 mg of morphine.[23]
• Oral doses of lornoxicam ranging from 16-24 mg daily were reported to be more effective than 300 mg of tramadol daily for pain management following knee surgery.[23]
• In studies focusing on dental pain (e.g., after third molar extraction), a single oral dose of lornoxicam 8 mg yielded a Number Needed to Treat (NNT) for at least 50% pain relief over 6 hours of 2.9 (95% CI 2.3 to 4.0). This level of efficacy is comparable to that of ibuprofen 200 mg.[13]
• Intramuscular administration of lornoxicam at doses greater than 8 mg was found to be at least as effective as 20 mg of intramuscular morphine.[10]
• A study on pain following third molar surgery demonstrated that lornoxicam treatment resulted in significantly lower median pain scores at 2 hours and 6 hours post-surgery compared to both flurbiprofen and placebo.[42] The consistent demonstration of efficacy in acute pain settings, particularly its performance against established analgesics like opioids and other NSAIDs, suggests a strong analgesic component to lornoxicam's action, possibly extending beyond peripheral anti-inflammatory effects. The NNT of 2.9 for an 8 mg dose in acute dental pain is indicative of robust efficacy. The potential for central analgesic effects, possibly mediated via endorphins as suggested by some preclinical data [10], could contribute to this pronounced analgesia in acute conditions, positioning lornoxicam as a valuable agent where rapid and potent pain relief is paramount, and potentially as an opioid-sparing alternative.
• Osteoarthritis and Rheumatoid Arthritis:
• In patients with osteoarthritis, lornoxicam administered at 4 mg three times daily (tid) or 8 mg twice daily (bid) was found to be as effective as diclofenac 50 mg tid.[17]
• A study in patients with activated osteoarthritis showed that lornoxicam provided significantly superior improvements in pain on movement, pain at rest, nocturnal pain, and duration of morning stiffness when compared to the selective COX-2 inhibitor rofecoxib.[18]
• For long-term management of rheumatoid arthritis, lornoxicam at doses of 8-16 mg/day demonstrated good safety and therapeutic activity, effectively controlling disease progression.[15]
• In another rheumatoid arthritis trial, lornoxicam 8 mg and 16 mg/day showed good therapeutic activity, comparable to diclofenac 150 mg/day. The 16 mg/day dose of lornoxicam was associated with a more pronounced action and better tolerability than diclofenac.[16] A clear dose-response relationship for analgesic efficacy has been observed, particularly in postoperative pain studies. Doses of 8mg and higher generally exhibit superior pain relief compared to lower doses or even some active comparators.[10] For example, one study directly investigating dose-effect relationships for single doses ranging from 4 mg to 32 mg found that 16 mg and 32 mg doses were superior to a 4 mg dose.[10] This implies that for severe acute pain, doses towards the higher end of the recommended range are likely necessary to achieve optimal analgesic outcomes.
• General Efficacy Profile: Lornoxicam is often described as combining the high therapeutic potency characteristic of the oxicam class with a potentially improved gastrointestinal tolerability profile, largely attributed to its short elimination half-life.[23] The consistent efficacy demonstrated across diverse pain models, including inflammatory joint pain and acute surgical pain, supports its broad applicability as both an analgesic and an anti-inflammatory agent. Its superior efficacy compared to some selective COX-2 inhibitors, such as rofecoxib in osteoarthritis [18], without a significantly worse short-term tolerability profile in that specific study, suggests that lornoxicam remains a competitive therapeutic option despite the availability of more COX-2 selective agents.

6. Dosage, Administration, and Formulations

The effective and safe use of lornoxicam necessitates adherence to appropriate dosage guidelines, consideration of patient-specific factors, and selection of suitable formulations.

General Dosage Guidelines

• For Pain Management (Acute): The typical daily dosage of lornoxicam for pain is 8 mg to 16 mg, administered in two or three divided doses. The maximum recommended daily dose is 16 mg.[37]
• For Osteoarthritis and Rheumatoid Arthritis (Chronic): The initial recommended daily dose is 12 mg, divided into two or three doses. The maintenance dose should generally not exceed 16 mg of lornoxicam per day.[39]
• Individualization of Dose: It is emphasized that the dosing regimen for any patient should be based upon their individual response to treatment.[37]
• Lowest Effective Dose and Duration: As with all NSAIDs, the principle of using the lowest effective dose for the shortest duration necessary to control symptoms should be applied to minimize the risk of adverse effects.[44]

Dosage in Special Populations

Adjustments to the standard dosage or specific precautions are necessary for certain patient populations:

• Elderly Patients (≥65 years): No specific dosage modification is generally required for elderly patients unless their renal or hepatic function is impaired. However, lornoxicam should be administered with precaution in this age group due to a higher susceptibility to gastrointestinal adverse effects.[37]
• Renal Impairment: For patients with mild to moderate renal impairment, the maximum recommended daily dose is 12 mg, divided into two or three doses.[39] Lornoxicam is contraindicated in patients with severe renal impairment.[37]
• Hepatic Impairment: For patients with moderate hepatic impairment, the maximum recommended daily dose is also 12 mg, divided into two or three doses.[39] It is contraindicated in patients with severe hepatic impairment.[37]
• Children and Adolescents (<18 years): Lornoxicam is generally not recommended for use in children and adolescents under the age of 18 due to a lack of sufficient data on safety and efficacy in this age group.[37]

Routes of Administration and Available Formulations

Lornoxicam is available in formulations suitable for both oral and parenteral (intramuscular, intravenous) administration, offering flexibility in clinical application.[3]

• Oral Formulations:
• Film-coated tablets (standard release).[12]
• Rapid-release film-coated tablets (e.g., Xefo Rapid) designed for faster onset of action.[12]
• Parenteral Formulations:
• Powder and solvent for solution for injection (for intramuscular or intravenous use).[3]
• Suppositories: While generally a formulation type for NSAIDs, and implied for lornoxicam in one source [12], the widespread availability of lornoxicam suppositories is less clearly detailed in the provided information.

The availability of multiple formulations allows clinicians to tailor treatment to specific patient needs and clinical scenarios. Parenteral formulations offer rapid systemic availability, bypassing potential issues with oral absorption and are particularly useful for severe acute pain (e.g., postoperative settings). Rapid-release oral tablets aim to expedite absorption compared to standard tablets, offering quicker pain relief for acute conditions when oral administration is preferred. Standard oral tablets provide a convenient option for the chronic management of conditions like osteoarthritis and rheumatoid arthritis. This versatility is a key advantage of lornoxicam. However, the necessity for dose adjustments in patients with renal and hepatic impairment [37], along with precautions in the elderly and the known impact of CYP2C9 metabolism on its pharmacokinetics, underscores the critical importance of individualized dosing strategies and careful patient selection to maintain a favorable risk-benefit profile.

Administration Instructions

Oral tablets of lornoxicam should generally be taken before meals with a sufficient quantity of liquid to optimize absorption and onset of action.[37]

Table 3: Approved Indications and Standard Dosages for Lornoxicam

Indication	Recommended Starting Dose	Maintenance Dose (if applicable)	Maximum Daily Dose	Route(s) of Administration	Notes on Special Populations (Elderly, Renal/Hepatic Impairment)	Reference(s)
Acute Mild to Moderate Pain	8-16 mg daily, divided into 2 or 3 doses	N/A	16 mg	Oral, Parenteral (IM/IV)	Elderly: Use with caution. Mild/Moderate Renal/Hepatic Impairment: Max 12 mg/day divided. Severe Impairment: Contraindicated.	37
Osteoarthritis	12 mg daily, divided into 2 or 3 doses	Maintenance dose not to exceed 16 mg daily	16 mg	Oral	Elderly: Use with caution unless renal/hepatic impairment present. Mild/Moderate Renal/Hepatic Impairment: Max 12 mg/day divided. Severe Impairment: Contraindicated.	37
Rheumatoid Arthritis	12 mg daily, divided into 2 or 3 doses	Maintenance dose not to exceed 16 mg daily	16 mg	Oral	Elderly: Use with caution unless renal/hepatic impairment present. Mild/Moderate Renal/Hepatic Impairment: Max 12 mg/day divided. Severe Impairment: Contraindicated.	37
Pain (General)	8-16 mg daily, divided into 2 or 3 doses	N/A	16 mg	Oral, Parenteral (IM/IV)	Children (<18 years): Not recommended.	37

N/A: Not Applicable. IM: Intramuscular. IV: Intravenous.

7. Safety Profile and Tolerability

The safety profile of lornoxicam is generally characteristic of non-steroidal anti-inflammatory drugs (NSAIDs), with gastrointestinal and neurological effects being the most commonly reported. While its shorter half-life may offer some advantages in terms of GI tolerability compared to longer-acting oxicams, vigilance for NSAID-class adverse events remains crucial.

Common Adverse Effects

Adverse effects associated with lornoxicam are typically mild to moderate in severity.

• Gastrointestinal System: The most frequently encountered adverse effects are gastrointestinal in nature. These include nausea, vomiting, diarrhea, dyspepsia, and abdominal pain.[3] It has been reported that approximately 20% of patients treated with lornoxicam may experience adverse reactions, with gastrointestinal events being the most common, occurring in about 14% of patients.[38]
• Nervous System: Headache and dizziness are also commonly reported neurological side effects.[3]

Lornoxicam's short half-life [22] is often presented as a potential advantage for improved GI tolerability when compared to other oxicams with significantly longer half-lives. The rationale is that a shorter duration of systemic exposure might lead to less sustained inhibition of COX-1 in the GI mucosa, thereby reducing the risk of mucosal damage. However, the actual incidence of GI adverse events with lornoxicam (reported at 14% in one meta-analysis [38]) remains significant and is typical for NSAIDs. This suggests that while the short half-life may offer some mitigation of risk, particularly when compared to very long-acting NSAIDs, it does not eliminate the inherent GI risk associated with its potent, non-selective COX-1 and COX-2 inhibition. The benefit is likely relative rather than absolute.

Serious Adverse Effects

Although less common, serious adverse effects can occur with lornoxicam therapy:

• Gastrointestinal System: More severe GI complications include bleeding, ulceration, and perforation. These risks are elevated with increasing doses, in elderly patients, and in individuals with a prior history of peptic ulcer disease.[3]
• Respiratory System: Bronchospasms have been reported, which can be particularly concerning in patients with pre-existing respiratory conditions like asthma.[11]
• Dermatological Reactions: Severe and potentially life-threatening skin reactions, although rare, have been associated with lornoxicam. These include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), exfoliative dermatitis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).[11] The occurrence of DRESS, which can present with fever, rash, lymphadenopathy, and/or facial swelling, necessitates immediate discontinuation of the drug.
• Hepatic System: Hepatotoxicity, including hepatic failure, hepatitis, jaundice, and cholestasis, has been reported, though these are considered very rare events.[37]
• Renal System: Nephrotoxicity can manifest in various forms, including acute renal failure, nephritis, and nephrotic syndrome. These are also considered very rare.[37]
• Hematological System: Effects on the blood system can include thrombocytopenia (low platelet count), leucopenia (low white blood cell count), anaemia, and prolonged bleeding time.[37]

Contraindications

Lornoxicam is contraindicated in several patient populations and clinical situations:

• Known hypersensitivity to lornoxicam or any of its excipients.[11]
• History of hypersensitivity reactions (e.g., asthma, rhinitis, angioedema, or urticaria) to other NSAIDs, including acetylsalicylic acid (aspirin).[11]
• Active or history of recurrent peptic ulcer, gastrointestinal bleeding, or perforation, particularly if related to previous NSAID therapy.[11]
• Severe heart failure.[11]
• Severe hepatic impairment.[11]
• Severe renal impairment (e.g., serum creatinine > 700 µmol/L).[11]
• Thrombocytopenia or other bleeding disorders.[11]
• During the third trimester of pregnancy.[11]
• For the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.[44]

Warnings and Precautions

Specific warnings and precautions should be observed when prescribing lornoxicam:

• Cardiovascular Risk: NSAIDs, as a class, may be associated with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. A European Union Committee for Medicinal Products for Human Use (CHMP) review in 2006 confirmed this risk for NSAIDs generally.[38] Lornoxicam should be used with caution in patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.[39]
• Gastrointestinal Risk: There is an increased risk of serious GI adverse events, including bleeding, ulceration, and perforation, which can be fatal. This risk is higher with increasing NSAID doses, in elderly patients, and in those with a history of peptic ulcer disease.[37]
• Renal Effects: Caution is advised in patients with mild to moderate renal impairment, and renal function should be monitored during therapy.[37]
• Hepatic Effects: Caution is necessary in patients with moderate hepatic impairment, and liver function should be monitored.[37]
• Bleeding Disorders: Lornoxicam reduces platelet aggregation and prolongs bleeding time; therefore, it should be used with care in patients with an increased bleeding tendency.[39]
• Use in Elderly: Elderly patients (≥65 years) have an increased frequency of adverse reactions to NSAIDs, especially GI bleeding and perforation. Lornoxicam should be used with caution in this population.[37]
• Pregnancy and Lactation: Lornoxicam is generally not recommended during pregnancy, especially during the first two trimesters, and is contraindicated in the third trimester. It is also not recommended during breastfeeding.[11] Lornoxicam may also impair female fertility.[48]
• Black Box Warnings: While the provided snippets do not explicitly mention a specific "black box warning" for lornoxicam in Europe or Japan, the general class warnings for NSAIDs regarding cardiovascular and GI risks are applicable. Pharmacovigilance databases like the FDA's Adverse Event Reporting System (FAERS) and Japan's JADER monitor NSAID-related adverse events, including small bowel bleeding, though lornoxicam is not singled out for specific box warnings in these particular documents.[11]

The extensive list of contraindications and precautions underscores that lornoxicam, despite any potential pharmacokinetic advantages conferred by its short half-life, is not inherently "safer" than other NSAIDs for high-risk patient groups without careful individual risk assessment and ongoing monitoring. The systemic effects of prostaglandin inhibition—affecting renal blood flow, GI mucosal protection, and cardiovascular homeostasis—are still significantly impacted by lornoxicam. Therefore, meticulous patient selection and diligent monitoring are paramount. The safety profile of lornoxicam reinforces the universal principle for all NSAID use: employ the lowest effective dose for the shortest possible duration, particularly in patients presenting with risk factors. The potential for severe skin reactions (SJS/TEN, DRESS) [11], though infrequent, represents a serious consideration that mandates immediate discontinuation of the drug at the first sign of such reactions.

Table 4: Common and Serious Adverse Effects of Lornoxicam [37]

System Organ Class	Adverse Effect	Frequency	Reference(s)
Gastrointestinal Disorders	Nausea, Dyspepsia, Indigestion, Abdominal pain, Vomiting, Diarrhoea	Common	37
	Gastritis, Gastric ulcer, Duodenal ulcer, Mouth ulceration	Uncommon	37
	Melaena, Haematemesis, Stomatitis, Oesophagitis, Gastroesophageal reflux, Dysphagia, Aphthous stomatitis, Glossitis, Perforated peptic ulcer, Gastrointestinal haemorrhage	Rare	37
Nervous System Disorders	Headache, Dizziness (mild and transient)	Common	37
	Somnolence, Paraesthesia, Dysgeusia, Tremor, Migraine	Rare	37
Skin and Subcutaneous Tissue Disorders	Rash, Pruritus, Hyperhidrosis, Rash erythematous, Urticaria, Alopecia, Angioedema	Uncommon	37
	Dermatitis, Purpura	Rare	37
	Oedema and bullous reactions, Stevens-Johnson syndrome, Toxic epidermal necrolysis	Very rare	37
	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)	Not known	37
Blood and Lymphatic System Disorders	Anaemia, Thrombocytopenia, Leucopenia, Prolonged bleeding time	Rare	37
	Ecchymosis	Very rare	37
Hepatobiliary Disorders	Increase in liver function tests (ALT or AST)	Uncommon	37
	Hepatic function abnormal	Rare	37
	Hepatotoxicity (e.g., hepatic failure, hepatitis, jaundice, cholestasis)	Very rare	37
Renal and Urinary Disorders	Nocturia, Micturition disorders, Increase in blood urea and creatinine levels	Rare	37
	Acute renal failure, Nephrotoxicity (e.g., nephritis, nephrotic syndrome)	Very rare	37
Immune System Disorders	Hypersensitivity, Anaphylactoid reaction and anaphylaxis	Rare	37
Respiratory, Thoracic and Mediastinal Disorders	Rhinitis	Uncommon	37
	Dyspnoea, Cough, Bronchospasm	Rare	37
Cardiac Disorders	Palpitations, Tachycardia, Oedema, Cardiac failure	Uncommon	37
Vascular Disorders	Flushing, Hypertension, Hot flush, Haemorrhage, Haematoma	Uncommon/Rare	37
General Disorders and Administration Site Conditions	Malaise, Face oedema	Uncommon	37
	Asthenia	Rare	37
Psychiatric Disorders	Insomnia, Depression	Uncommon	37
	Confusion, Nervousness, Agitation	Rare	37

8. Drug Interactions

Lornoxicam, like other NSAIDs, is subject to a range of clinically significant drug interactions that can alter its efficacy or safety, or that of co-administered drugs. These interactions can be broadly categorized as pharmacodynamic or pharmacokinetic.

Pharmacodynamic Interactions

These interactions involve additive or synergistic effects on physiological systems:

• Other NSAIDs (including Aspirin): Co-administration significantly increases the risk of adverse effects, particularly gastrointestinal bleeding and ulceration.[3] Lornoxicam may also diminish the antiplatelet effect and cardioprotective benefits of low-dose aspirin.[4]
• Anticoagulants (e.g., Warfarin, Heparin, Phenprocoumon): Lornoxicam can enhance the effects of anticoagulants, leading to an increased risk of bleeding and hemorrhage.[35] Careful monitoring of coagulation parameters (e.g., INR) is essential.
• Anti-platelet Agents (e.g., Clopidogrel) and Selective Serotonin Reuptake Inhibitors (SSRIs): Concurrent use increases the risk of gastrointestinal bleeding due to additive effects on platelet function and/or GI mucosa.[37]
• Corticosteroids (e.g., Prednisone, Dexamethasone): The combination with lornoxicam elevates the risk of gastrointestinal ulceration or bleeding.[3]
• Diuretics (e.g., Furosemide, Hydrochlorothiazide), ACE Inhibitors (e.g., Enalapril, Lisinopril), and Angiotensin II Receptor Antagonists (ARBs) (e.g., Losartan, Irbesartan): Lornoxicam can reduce the antihypertensive and natriuretic effects of these drugs. Furthermore, this combination can increase the risk of nephrotoxicity, particularly in dehydrated or elderly patients, and may also increase the risk of hyperkalemia.[4] The risk of nephrotoxicity is amplified when lornoxicam is combined with drugs affecting renal function or known nephrotoxins. NSAIDs can impair renal function by inhibiting prostaglandin synthesis, which is vital for maintaining renal blood flow and glomerular filtration rate, especially in compromised states. Diuretics can induce volume depletion, rendering the kidneys more susceptible to NSAID-induced injury. ACE inhibitors and ARBs also impact renal hemodynamics and, when combined with NSAIDs, can precipitate acute kidney injury.

Pharmacokinetic Interactions

These interactions involve alterations in the absorption, distribution, metabolism, or excretion of lornoxicam or the co-administered drug:

• Lithium: Lornoxicam can decrease the renal clearance of lithium, leading to increased plasma lithium levels and an elevated risk of lithium toxicity.[35] Lithium levels should be monitored closely if co-administration is necessary.
• Methotrexate: Concurrent use can increase methotrexate serum concentrations by reducing its renal excretion, thereby enhancing methotrexate toxicity, particularly hematological and GI toxicity.[4]
• Digoxin: Lornoxicam may decrease the renal excretion of digoxin, potentially leading to increased digoxin plasma levels and risk of toxicity.[4] Digoxin levels should be monitored.
• Ciclosporin: The risk of nephrotoxicity may be increased when lornoxicam is co-administered with ciclosporin, possibly due to additive effects on renal prostaglandin synthesis or altered ciclosporin levels.[35]
• Cimetidine: Cimetidine, an H2-receptor antagonist, can increase plasma concentrations of lornoxicam, likely by inhibiting its metabolism.[4]
• Sulphonylureas (e.g., Glibenclamide): Lornoxicam may enhance the hypoglycaemic effect of sulphonylureas, possibly through displacement from plasma protein binding sites or effects on glucose metabolism.[4] Blood glucose monitoring is advised.
• CYP2C9 Inducers (e.g., Rifampicin): Since lornoxicam is primarily metabolized by CYP2C9, potent inducers of this enzyme, such as rifampicin, can decrease lornoxicam plasma concentrations, potentially reducing its efficacy.[37]
• CYP2C9 Inhibitors (e.g., Fluconazole, Amiodarone, Miconazole): Conversely, potent inhibitors of CYP2C9 can significantly increase lornoxicam plasma concentrations and prolong its half-life, thereby increasing the risk of toxicity.[4] Co-administration with strong CYP2C9 inhibitors requires caution and potentially dose adjustment of lornoxicam. This is a critical consideration due to lornoxicam's heavy reliance on CYP2C9 for its clearance.
• Tacrolimus: Concurrent administration with lornoxicam may increase the risk of nephrotoxicity.[37] Renal function should be closely monitored.
• Pemetrexed: Lornoxicam may decrease the renal clearance of pemetrexed, potentially increasing its toxicity.[46]
• Cholestyramine and Colestipol: These bile acid sequestrants can decrease the absorption of lornoxicam from the GI tract, potentially reducing its serum concentration and efficacy.[4] Administration times should be staggered.

The extensive list of potential drug interactions, particularly those affecting bleeding risk, renal function, and lornoxicam's own metabolism via CYP2C9, necessitates a thorough review of a patient's concomitant medications before initiating lornoxicam. Such interactions often require dose adjustments, enhanced clinical or laboratory monitoring, or, in some cases, avoidance of certain combinations to ensure patient safety.

Table 5: Clinically Significant Drug Interactions with Lornoxicam

Interacting Drug/Class	Potential Effect on Lornoxicam or Co-administered Drug	Probable Mechanism	Management Recommendation	Reference(s)
Other NSAIDs (incl. Aspirin)	Increased risk of GI adverse effects (bleeding, ulceration); Lornoxicam may ↓ efficacy of low-dose aspirin.	Pharmacodynamic synergism (GI toxicity); Competition for COX binding (aspirin efficacy).	Avoid concomitant use if possible; if aspirin for cardioprotection, assess risk/benefit.	3
Anticoagulants (e.g., Warfarin)	Increased risk of bleeding.	Pharmacodynamic (additive antiplatelet/anticoagulant effects); Potential displacement from protein binding.	Avoid if possible; if unavoidable, monitor coagulation parameters (INR) very closely.	35
Anti-platelet Agents (e.g., Clopidogrel), SSRIs	Increased risk of GI bleeding.	Pharmacodynamic (additive effects on platelet function and/or GI mucosa).	Use with caution; consider gastroprotective agents in high-risk patients.	37
Corticosteroids	Increased risk of GI ulceration or bleeding.	Pharmacodynamic (synergistic damage to GI mucosa).	Use with caution, especially long-term; consider gastroprotection.	3
Diuretics, ACE Inhibitors, ARBs	Decreased antihypertensive effect; Increased risk of nephrotoxicity, acute kidney injury, hyperkalemia.	Inhibition of renal prostaglandin synthesis (reduces diuretic/antihypertensive effect, impairs renal blood flow).	Monitor blood pressure and renal function closely; ensure adequate hydration; consider dose adjustments.	4
Lithium	Increased lithium plasma levels and risk of toxicity.	Decreased renal clearance of lithium.	Avoid if possible; if co-administered, monitor lithium levels frequently and adjust lithium dose.	35
Methotrexate	Increased methotrexate levels and risk of toxicity.	Decreased renal clearance of methotrexate.	Avoid high-dose methotrexate; use with caution at low doses with close monitoring of methotrexate levels and signs of toxicity.	4
Digoxin	Increased digoxin plasma levels and risk of toxicity.	Decreased renal clearance of digoxin.	Monitor digoxin levels and for signs of toxicity; adjust digoxin dose if needed.	4
Ciclosporin, Tacrolimus	Increased risk of nephrotoxicity.	Additive nephrotoxic effects; altered renal hemodynamics.	Avoid if possible; if co-administered, monitor renal function very closely.	35
CYP2C9 Inhibitors (e.g., Fluconazole, Amiodarone)	Increased lornoxicam plasma concentrations and risk of toxicity.	Inhibition of lornoxicam metabolism via CYP2C9.	Use with caution; consider lornoxicam dose reduction; monitor for lornoxicam adverse effects.	4
CYP2C9 Inducers (e.g., Rifampicin)	Decreased lornoxicam plasma concentrations and potential loss of efficacy.	Induction of lornoxicam metabolism via CYP2C9.	Monitor for reduced lornoxicam efficacy; consider lornoxicam dose increase if necessary.	37
Cimetidine	Increased lornoxicam plasma levels.	Inhibition of lornoxicam metabolism (mechanism less clear, possibly CYP inhibition).	Use with caution; monitor for lornoxicam adverse effects.	4
Sulphonylureas (e.g., Glibenclamide)	Potential enhancement of hypoglycaemic effect.	Possible displacement from plasma protein binding.	Monitor blood glucose levels closely, especially at initiation or dose change.	4
Cholestyramine/Colestipol	Decreased absorption of lornoxicam.	Binding of lornoxicam in the GI tract.	Administer lornoxicam at least 1 hour before or 4-6 hours after bile acid sequestrants.	4

9. Regulatory Status and International Availability

Lornoxicam has a varied regulatory status across different global regions, reflecting its long history and established use in many countries.

• Japan (PMDA - Pharmaceuticals and Medical Devices Agency): Lornoxicam is approved for medical use in Japan.[1] While a specific initial approval date from the PMDA was not explicitly found in the provided snippets [50], general information indicates its patenting in 1977 and approval for medical use starting in 1997, with specific mention of its approval in Japan.[11] The existence of a Lornoxicam Drug Master File (JDMF) in Japan further supports its regulatory processing and availability in this market.[3]
• Europe (EMA - European Medicines Agency and National Authorities): Lornoxicam is marketed in numerous European countries under various brand names, including Xefo and Xefocam.[3] It was subject to an Article 30 referral procedure under the EMA to harmonize the Summaries of Product Characteristics (SPCs), labelling, and package leaflets across EU Member States. This referral was initiated due to existing divergences in the nationally approved product information concerning its indications for short-term relief of acute mild to moderate pain, and symptomatic relief of pain and inflammation in osteoarthritis and rheumatoid arthritis. The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on February 22, 2007, recommending this harmonization. Subsequently, the European Commission issued a final, legally binding decision on May 29, 2007, implementing the harmonized product information across the EU.[19] This action highlights the complexities of drug regulation across multiple jurisdictions even within the EU prior to such harmonization efforts, where differing national approvals could lead to inconsistencies in prescribing information and use. The CHMP also conducted a broader Europe-wide review of NSAIDs in 2006, which concluded that NSAIDs, as a class, are associated with an increased risk of cardiovascular events, though the overall benefit-risk balance was still considered favorable.[49]
• United States (FDA - Food and Drug Administration): The provided information does not indicate that lornoxicam is approved for use in the United States. DrugBank [4] does not list US approval, and other snippets discussing regulatory agencies do not confirm FDA approval for lornoxicam.[28]
• Canada (Health Canada): Specific approval information for lornoxicam in Canada was not found in the provided materials.[55]
• Australia (TGA - Therapeutic Goods Administration): Specific approval information for lornoxicam in Australia was not explicitly found.[27] However, one document mentions lornoxicam in a list of non-selective COX inhibitors studied in an Australian context, which might imply some level of recognition or availability, though direct TGA approval is not confirmed by these snippets.[58]
• Other Regions: Lornoxicam is widely available internationally, reportedly in 31 countries across the Middle East, Far East, and South America, in addition to its presence in Europe and Japan.[13] Specific countries where it is available include Ecuador, Spain, Venezuela, Portugal, India, Pakistan, Turkey, Vietnam, Egypt, Georgia, Colombia, Italy, China, Bosnia & Herzegovina, Ireland, Lithuania, Latvia, Poland, Romania, Serbia, Slovakia, Bulgaria, Estonia, Greece, Denmark, Switzerland, Hungary, Israel, Austria, and Russia.[29]
• Brand Names: Common international brand names include Xefo, Xefocam, Lorcam, Acabel, Safem, Taigalor, and Telos.[8] A more extensive list of brand names is available in reference.[29]

The widespread international availability of lornoxicam, with the notable exception of clear FDA approval in the US based on the provided information, suggests that it has found a significant therapeutic niche globally. This is likely attributable to its perceived balance of potent efficacy and a pharmacokinetic profile that may offer advantages over other NSAIDs in certain clinical contexts. Its approval and use in major markets like Japan and across Europe further solidify its role in pain and inflammation management.

Table 6: Regulatory Status and Brand Names of Lornoxicam in Key Regions

Region/Authority	Approval Status	Key Brand Names in Region (Examples)	Date of Approval (if available) / Key Regulatory Actions	Reference(s)
Japan (PMDA)	Approved	Lornoxicam (generic), Taigalor, Xefo	Approved for medical use since 1997 (general statement, specific PMDA date not in snippets). JDMF exists.	1
Europe (EMA & National Authorities)	Approved (harmonized SPC across EU)	Xefo, Xefocam, Lorcam, Acabel	Article 30 referral positive opinion Feb 22, 2007; EC decision May 29, 2007, for harmonized SPC.	3
United States (FDA)	Not explicitly stated as approved; likely not approved.	N/A	DrugBank does not list US approval.	4
Canada (Health Canada)	Unknown from provided information.	N/A	No specific approval data found.	55
Australia (TGA)	Unknown from provided information (though mentioned in an Australian context study).	N/A	No specific TGA approval data found.	27
Various (Other International Regions)	Approved in numerous countries across Middle East, Far East, South America, etc.	Various 29	Available in ~31 countries.	13

N/A: Not Applicable or Not Available from provided snippets.

10. Comparative Efficacy and Safety

Evaluating lornoxicam in the context of other NSAIDs, particularly other oxicams, and even opioids, provides valuable insights into its therapeutic positioning.

Comparison with other Oxicams (Piroxicam, Meloxicam, Tenoxicam)

Lornoxicam distinguishes itself from other members of the oxicam class primarily through its pharmacokinetic profile:

• Elimination Half-Life: Lornoxicam possesses a relatively short elimination half-life of 3-5 hours.[6] This is in stark contrast to other oxicams like piroxicam (half-life ~50 hours [27]) and tenoxicam (which also typically has a longer half-life). This shorter half-life is frequently suggested as an advantage for lornoxicam, potentially leading to improved tolerability, especially concerning gastrointestinal side effects, due to less drug accumulation and a shorter duration of COX-1 inhibition.[6] This pharmacokinetic difference is a key differentiating factor and is often linked to a theoretically better GI safety profile compared to its longer-acting congeners. While direct, large-scale head-to-head GI safety outcome studies against other oxicams are not extensively detailed in the provided information, the mechanistic rationale for this potential benefit is strong.
• Potency: In vitro, lornoxicam has been reported to be approximately 100-fold more potent than tenoxicam in inhibiting PGD₂ formation in rat polymorphonuclear leukocytes.[10]
• Membrane Interaction and COX Access: One study comparing meloxicam, piroxicam, and tenoxicam (lornoxicam not directly included in this part of the comparison) regarding their interaction with lipid monolayers (as a model for cell membrane interaction, which is a prerequisite for accessing COX enzymes) found that meloxicam had the highest ability to modify membrane fluidity, followed by piroxicam, and then tenoxicam. Another part of the same study or a related one suggested an order of insertion into the hydrocarbon region of the bilayer as meloxicam > tenoxicam > lornoxicam, and linked this property to their efficacy as enzyme inhibitors.[59] These findings on membrane interaction are complex and require careful interpretation in the context of overall in vivo efficacy.
• Anti-hyperalgesic Activity: In a preclinical model of central hyperalgesia, lornoxicam, piroxicam, and meloxicam (administered at their respective ED₅₀ doses for anti-inflammatory effect) all significantly reduced formalin-induced hyperalgesia. However, only lornoxicam was found to be fully effective in preventing the development of hyperalgesia. This finding suggests a potential dissociation between anti-inflammatory and anti-hyperalgesic activities, with lornoxicam possibly having a more pronounced effect on blocking central sensitization mechanisms, which could contribute to its strong analgesic profile.[60]

Comparison with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Lornoxicam has been compared to several other commonly used NSAIDs in clinical trials:

• Diclofenac: In patients with osteoarthritis, lornoxicam (administered as 4 mg tid or 8 mg bid) demonstrated efficacy comparable to diclofenac 50 mg tid, with similar tolerability profiles.[17] In rheumatoid arthritis, lornoxicam 16 mg/day showed good therapeutic activity, comparable to diclofenac 150 mg/day, and was associated with a potentially sharper onset of action and better tolerability than diclofenac in one study.[16]
• Ibuprofen: For acute postoperative dental pain, lornoxicam 8 mg was found to have efficacy comparable to ibuprofen 200 mg.[13] In the treatment of primary dysmenorrhea, lornoxicam 8 mg bid was comparable in both efficacy and safety to ibuprofen 400 mg bid.[61]
• Naproxen: Some sources suggest that lornoxicam has an improved gastrointestinal toxicity profile when compared to naproxen.[23] A meta-analysis also indicated that lornoxicam was associated with a reduced risk of GI adverse drug reactions compared to naproxen.[38]
• Rofecoxib (a selective COX-2 inhibitor): In a study involving patients with activated osteoarthritis, lornoxicam demonstrated significantly superior analgesic and anti-inflammatory effects compared to rofecoxib. While GI symptoms showed a slight trend towards being less frequent with rofecoxib, lornoxicam was not found to be inferior in overall tolerability in this particular trial.[18]

Comparison with Opioid Analgesics (Morphine, Tramadol)

Lornoxicam has also shown favorable efficacy when compared to certain opioid analgesics, particularly in acute pain settings:

• Morphine: In the management of pain after oral surgery, lornoxicam at doses ≥8 mg was reported to be more effective than 10 mg of morphine.[23] Intramuscular lornoxicam at doses greater than 8 mg was found to be at least as effective as 20 mg of intramuscular morphine for postoperative pain, with the added benefit of a significantly lower incidence of adverse effects compared to morphine.[10]
• Tramadol: Oral doses of lornoxicam ranging from 16-24 mg daily were reported to be more effective than tramadol 300 mg daily for pain relief following knee surgery.[23]

The consistent efficacy of lornoxicam across various pain models, including inflammatory joint pain and acute surgical pain, supports its broad applicability as a potent analgesic and anti-inflammatory agent. Its performance against opioids in some acute pain scenarios, often with better tolerability, highlights lornoxicam's potential role in multimodal and opioid-sparing pain management strategies. Furthermore, its demonstrated efficacy against a COX-2 selective inhibitor like rofecoxib in osteoarthritis [18] suggests that for certain patients, a potent balanced COX inhibitor might offer superior pain relief, although the inherent GI risk associated with non-selective COX inhibition remains a crucial consideration.

11. Conclusion and Future Perspectives

Summary of Lornoxicam's Profile

Lornoxicam is a potent, non-selective non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Its pharmacological profile is characterized by robust analgesic, anti-inflammatory, and antipyretic effects, primarily mediated through the strong inhibition of both COX-1 and COX-2 enzymes. A key distinguishing feature is its relatively rapid absorption and short elimination half-life (3-5 hours) compared to other oxicams, which is proposed to contribute to a potentially better gastrointestinal tolerability profile without compromising its high therapeutic potency. It is extensively metabolized by CYP2C9, leading to significant interindividual pharmacokinetic variability influenced by genetic polymorphisms.

Place in Therapy

Lornoxicam has established itself as a valuable therapeutic option for a wide array of painful and inflammatory conditions. Its indications span acute mild to moderate pain, postoperative pain (including dental and orthopedic surgery), and the symptomatic management of chronic inflammatory joint diseases such as osteoarthritis and rheumatoid arthritis, as well as conditions like sciatica and low back pain. The availability of both oral (including rapid-release) and parenteral formulations allows for flexibility in administration, making it suitable for rapid pain relief in acute settings and for convenient maintenance therapy in chronic conditions. The balance of potent efficacy, often comparable or superior to other NSAIDs and even some opioids in specific acute pain scenarios, combined with a pharmacokinetic profile that may offer tolerability advantages over longer-acting NSAIDs, positions lornoxicam as a useful alternative in the NSAID armamentarium.

Key Considerations for Clinical Use

Despite its benefits, the clinical use of lornoxicam requires careful consideration of several factors:

• Gastrointestinal Risk: As a non-selective COX inhibitor, lornoxicam carries the inherent risk of GI adverse events (e.g., dyspepsia, ulceration, bleeding), which are common to the NSAID class. While its short half-life may mitigate this risk to some extent compared to longer-acting agents, it does not eliminate it.
• Cardiovascular Risk: Standard NSAID class warnings regarding potential cardiovascular thrombotic events apply to lornoxicam.
• CYP2C9-Mediated Variability: The significant interindividual variability in lornoxicam pharmacokinetics due to CYP2C9 genetic polymorphisms is a critical factor. Poor metabolizers can experience substantially increased drug exposure and a prolonged half-life, heightening the risk of adverse effects. This underscores the importance of individualized dosing approaches.
• Special Populations: Dose adjustments and cautious use are necessary in elderly patients and individuals with renal or hepatic impairment. It is generally not recommended for use in children and is contraindicated in the third trimester of pregnancy.
• Drug Interactions: Lornoxicam is subject to numerous clinically significant drug interactions, particularly with anticoagulants, other NSAIDs, methotrexate, lithium, and drugs affecting CYP2C9 activity.

The main clinical challenge and, concurrently, the opportunity for lornoxicam, lies in effectively leveraging its notable potency and favorable rapid kinetics while diligently mitigating the risks associated with its non-selective COX inhibition and its CYP2C9-dependent metabolic pathway. The ideal application of lornoxicam is in situations demanding strong and rapid analgesia or anti-inflammatory effects, where patient-specific factors—such as baseline GI and cardiovascular risk, renal and hepatic function, concomitant medications, and potentially CYP2C9 genotype—are meticulously evaluated to optimize dosing and treatment duration.

Future Perspectives

Lornoxicam exemplifies the ongoing quest within pharmaceutical research for NSAIDs that can deliver maximal therapeutic efficacy while minimizing mechanism-based toxicities. While its short elimination half-life represents a step toward potentially improved GI safety within the oxicam class, the significant influence of pharmacogenetics (specifically CYP2C9 polymorphisms) on its disposition highlights the growing importance of personalized medicine approaches, even for well-established drug classes like NSAIDs.

Future research directions could productively focus on:

• Pharmacogenetic-Guided Dosing: Further studies and development of clinical guidelines for CYP2C9 genotype-guided dosing of lornoxicam could help optimize efficacy and minimize adverse drug reactions in diverse patient populations.
• Comparative Long-Term Safety Studies: Well-designed, large-scale, long-term comparative safety studies, particularly focusing on gastrointestinal and cardiovascular outcomes against other commonly used NSAIDs (including selective COX-2 inhibitors and other non-selective NSAIDs with different pharmacokinetic profiles), would further delineate lornoxicam's precise risk-benefit profile in chronic use.
• Role in Multimodal Analgesia: Continued exploration of lornoxicam's role in multimodal, opioid-sparing analgesic regimens is warranted, given its potent analgesic effects and favorable comparisons with opioids in some acute pain settings.
• Novel Formulations: Research into novel formulations or drug delivery systems that might further enhance its safety margin (e.g., by targeted delivery or further optimizing its release profile) without compromising its efficacy could also be beneficial.

In conclusion, lornoxicam remains a clinically relevant NSAID, offering a potent and relatively rapid-acting option for pain and inflammation. Its optimal use requires a comprehensive understanding of its pharmacology, careful patient selection, and an individualized approach to dosing, particularly considering its metabolic pathway and potential for drug interactions.## Lornoxicam: A Comprehensive Pharmacological Review

1. Introduction to Lornoxicam

Overview and Therapeutic Significance

Lornoxicam, also known by its chemical name chlortenoxicam, is a potent non-steroidal anti-inflammatory drug (NSAID) belonging to the oxicam class of therapeutic agents.[1] It is well-recognized for its pronounced analgesic, anti-inflammatory, and antipyretic properties.[1] The primary clinical applications of lornoxicam include the management of acute mild to moderate pain, and the symptomatic relief of pain and inflammation associated with a spectrum of rheumatic conditions, most notably osteoarthritis and rheumatoid arthritis.[1]

A key distinguishing characteristic of lornoxicam, when compared with other members of the oxicam family, is its potent inhibition of prostaglandin biosynthesis. This potent action is coupled with a relatively short plasma elimination half-life, typically observed to be between 3 to 5 hours.[1] This pharmacokinetic characteristic is of particular interest as it is suggested to contribute to a potentially more favorable gastrointestinal (GI) tolerability profile. The rationale behind this improved tolerability lies in the reduced likelihood of drug accumulation and less sustained inhibition of cyclooxygenase-1 (COX-1) in the gastrointestinal mucosa, an enzyme crucial for maintaining gastric mucosal integrity.

The development of lornoxicam, characterized by this specific combination of high potency and a short half-life, appears to reflect a strategic pharmacological approach. This approach aims to maximize therapeutic efficacy, characteristic of the oxicam class, while potentially minimizing the cumulative GI toxicity often associated with longer-acting NSAIDs. Oxicams as a class are renowned for their strong anti-inflammatory effects; however, this efficacy is often counterbalanced by a significant risk of GI adverse events, partly due to their typically long elimination half-lives leading to prolonged COX-1 inhibition in the GI mucosa. Lornoxicam's potent inhibition of prostaglandin synthesis ensures robust anti-inflammatory and analgesic action.[1] Its comparatively short half-life of 3-5 hours [22] is a deliberate deviation from other oxicams, such as piroxicam, which has a half-life of approximately 50 hours.[27] This shorter duration of action is theorized to diminish the continuous insult to the GI lining, potentially translating to better GI tolerability.[23] Consequently, lornoxicam can be viewed as a pharmacological endeavor to optimize the benefit-risk ratio within the oxicam class, aiming for high efficacy with a reduced window for the manifestation of mechanism-based side effects.

Development and International Availability

Lornoxicam was first patented in 1977, with its initial approval for medical use following in 1997.[11] It has secured regulatory approval in Japan [1] and is currently marketed under various brand names (e.g., Xefo, Lorcam) in a multitude of countries spanning Europe, the Middle East, the Far East, and South America.[13] This widespread availability underscores its established role in pain and inflammation management globally. The drug's characteristics and market presence highlight the ongoing clinical demand for effective NSAIDs that also offer improved safety profiles. The development pathway of lornoxicam is illustrative of the persistent pharmaceutical challenge: to effectively dissociate potent anti-inflammatory and analgesic activity from the mechanism-based toxicities, particularly the GI and cardiovascular risks that are inherent to the inhibition of cyclooxygenase enzymes.

2. Chemical and Physicochemical Properties

A thorough understanding of lornoxicam's chemical and physicochemical characteristics is essential for comprehending its pharmacological behavior, guiding formulation strategies, and ensuring its safe and effective use.

Chemical Identity

Lornoxicam is chemically identified as:

• IUPAC Name: 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide [1] or, with slightly different nomenclature, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide-1,1-dioxide.[2]
• Synonyms: Commonly used synonyms include chlortenoxicam, Ro 13-9297, and TS 110.[2]
• Chemical Class: Lornoxicam is classified as an oxicam and is a thienothiazine derivative.[1]

Molecular Structure

Lornoxicam is a thienothiazine-derived monocarboxylic acid amide. Its structure arises from the formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine.33

Key structural representations include:

• SMILES (Simplified Molecular Input Line Entry System): CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3.[1]
• InChIKey (International Chemical Identifier Key): WLHQHAUOOXYABV-UHFFFAOYSA-N.[1] The molecular architecture features the characteristic enol-type acidic proton of the oxicam class, a thienothiazine heterocyclic system, and a pyridine moiety, all contributing to its pharmacological activity and physicochemical properties.

Identifiers and Physical State

• Molecular Formula: C₁₃H₁₀ClN₃O₄S₂.[1]
• Molecular Weight: Approximately 371.8 g/mol. Various sources report values ranging from 371.8 g/mol to 371.82 g/mol.[1]
• CAS Number: 70374-39-9.[1]
• DrugBank ID: DB06725.[1]
• Appearance: Lornoxicam is described as a crystalline solid.[2] Its color can range from light orange to yellow or even green as a powder or crystal.[7]

Solubility and Related Properties

The solubility characteristics of lornoxicam are crucial for its absorption and formulation:

• Solubility in Organic Solvents: It is soluble in common organic solvents, including ethanol (approximately 1 mg/mL), dimethyl sulfoxide [2], and dimethylformamide (DMF, approximately 1 mg/mL).[2]
• Aqueous Solubility: Lornoxicam is reported to be soluble in water at a concentration of 1 mg/mL; however, aqueous solutions are not recommended for storage beyond one day due to potential stability issues.[2]
• pH-Dependent Solubility: Being a weak acid, lornoxicam's aqueous solubility is markedly pH-dependent. Its solubility increases exponentially as the pH rises from 3.0 to 9.0.[12] This property is critical for its dissolution in different segments of the gastrointestinal tract. In the acidic environment of the stomach (pH 1-2), lornoxicam, with a pKa of 4.7, will exist predominantly in its un-ionized, less water-soluble form. Conversely, in the more neutral or slightly alkaline pH of the small intestine (pH 6-7.4), the proportion of the ionized, more water-soluble form increases, thereby enhancing its dissolution.[12] Slow or incomplete dissolution can significantly delay absorption and the onset of action, which is particularly undesirable for an analgesic medication. This inherent characteristic explains the pharmaceutical focus on developing formulations designed to overcome this limitation, such as "quick-release" tablets [12] or formulations that incorporate alkaline agents to create a local microenvironment with a higher pH, thereby accelerating the dissolution process.[12]
• pKa: The acidity constant (pKa) of lornoxicam is 4.7.[12]
• Melting Point: Lornoxicam melts with decomposition at a range of 225-230°C [32] or 229-231°C.[7]
• Log P (Partition Coefficient): The n-octanol/pH 7.4 buffer partition coefficient is 1.8 [32], indicating moderate lipophilicity.
• UV/Vis Absorption Maxima (λ_max): Lornoxicam exhibits characteristic UV/Vis absorption maxima at 270 nm and 381 nm.[2] Another source reports a λ_max at 371 nm.[32]

Crystal Structure

Detailed crystallographic data for lornoxicam are available, including Crystallography Open Database (COD) numbers and space group information (e.g., Hermann-Mauguin space group symbol P 21 21 21).[1] This indicates a well-characterized solid-state structure, which is fundamental for understanding solid-state properties, polymorphism, and for advanced pharmaceutical formulation design.

The challenge of formulating a poorly soluble weak acid like lornoxicam for rapid and consistent oral absorption is a common consideration in pharmaceutical sciences. The strategies employed, such as the use of alkaline excipients or the investigation of cyclodextrin inclusion complexes [12], reflect broader industry approaches to enhance the bioavailability and therapeutic utility of such drug candidates. This also underscores the value of parenteral formulations [7] as alternatives when rapid onset and complete systemic availability are paramount.

Table 1: Physicochemical Properties of Lornoxicam

Property	Value	Reference(s)
IUPAC Name	6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide	1
Molecular Formula	C<sub>13</sub>H<sub>10</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub>	1
Molecular Weight	~371.8 g/mol	1
CAS Number	70374-39-9	1
DrugBank ID	DB06725	1
Appearance	Crystalline solid; light orange to yellow to green powder/crystal	2
Solubility (Water)	1 mg/mL (pH-dependent; unstable beyond 1 day)	2
Solubility (Ethanol)	~1 mg/mL	2
Solubility (DMSO)	~2 mg/mL 2; >5 mg/mL (warmed) 34	2
Solubility (DMF)	~1 mg/mL	2
pKa	4.7	12
Melting Point	225-230°C (dec.) or 229-231°C (dec.)	7
Log P (n-octanol/pH 7.4)	1.8	32
UV/Vis λ<sub>max</sub>	270 nm, 381 nm (or 371 nm)	2

3. Mechanism of Action and Pharmacodynamics

Primary Mechanism: Cyclooxygenase (COX) Inhibition

Lornoxicam exerts its therapeutic effects—analgesia, anti-inflammation, and antipyresis—through the potent inhibition of cyclooxygenase (COX) enzymes.[1] COX enzymes, existing as two main isoforms, COX-1 and COX-2, are critical for the biosynthesis of prostaglandins and thromboxanes from their precursor, arachidonic acid. By inhibiting these enzymes, lornoxicam effectively curtails the production of these eicosanoids, which are pivotal mediators of inflammation, pain sensitization, and fever.[1]

COX Isoform Selectivity and Potency

Lornoxicam is characterized by a balanced inhibitory profile against both COX-1 and COX-2 isoforms.[3] In vitro studies have quantified this potency, with reported IC₅₀ values (the concentration required to inhibit enzyme activity by 50%) of approximately 3 nM for COX-1 (assessed by inhibition of thromboxane B2 production in human erythroleukemic cells) and 8 nM for COX-2 (assessed by inhibition of prostaglandin F_1α formation in Mono-Mac-6 cells).[2] These low nanomolar IC₅₀ values underscore the high potency of lornoxicam against both cyclooxygenase isoforms. The similar magnitude of these values confirms its non-selective nature, meaning it does not preferentially inhibit one isoform over the other. This balanced, potent inhibition is a double-edged sword: while ensuring robust analgesic and anti-inflammatory effects (largely attributed to COX-2 inhibition), it inherently carries the risk of mechanism-based side effects, particularly gastrointestinal toxicity, due to the concurrent potent inhibition of the constitutively expressed COX-1 enzyme. Even though lornoxicam's short half-life is intended to mitigate some of these risks, the fundamental mechanism of potent COX-1 inhibition remains, explaining why GI adverse events are commonly reported.[3]

Additional Pharmacodynamic Effects

Beyond its primary action on COX enzymes, lornoxicam may exhibit other pharmacodynamic effects that contribute to its overall therapeutic profile:

• Leukotriene Pathway Modulation: It has been reported that, unlike some other NSAIDs, lornoxicam's inhibition of cyclooxygenase does not lead to a significant increase in the formation of leukotrienes.[4] This suggests that the metabolic shunting of arachidonic acid from the COX pathway to the 5-lipoxygenase pathway (which produces leukotrienes) may be minimal with lornoxicam. This characteristic could be clinically relevant. Arachidonic acid serves as a common precursor for both prostaglandins (via COX enzymes) and leukotrienes (via 5-lipoxygenase). If the COX pathway is substantially blocked, there is a potential for substrate (arachidonic acid) to be shunted towards the 5-lipoxygenase pathway, leading to increased production of leukotrienes. Elevated levels of leukotrienes are implicated in the pathophysiology of certain conditions, such as bronchoconstriction and other hypersensitivity reactions, particularly in susceptible individuals (e.g., those with aspirin-exacerbated respiratory disease, AERD). If lornoxicam indeed avoids or minimizes this metabolic shunting, as suggested by some sources [4], it might offer a theoretical safety advantage in patients prone to leukotriene-mediated adverse reactions. However, this potential benefit would need to be carefully weighed against the risks associated with its COX-1 inhibitory activity.
• Central Analgesic Mechanisms: There is some evidence to suggest that lornoxicam may also exert analgesic effects through central nervous system mechanisms, possibly by modulating endogenous opioid pathways, such as increasing the levels of dinorphin and beta-endorphin.[10]
• Anti-inflammatory Cellular Effects: Lornoxicam has been shown to inhibit the migration of polymorphonuclear (PMN) leukocytes and to reduce the release of superoxide radicals from these cells.[10] Furthermore, it can inhibit the release of platelet-derived growth factor (PDGF) from human platelets and has been observed to stimulate the synthesis of proteoglycans in cartilage in tissue culture models.[10]
• Inhibition of Other Inflammatory Mediators: In cell-based assays, lornoxicam has demonstrated the ability to reduce lipopolysaccharide (LPS)-induced production of nitric oxide (NO) and the pro-inflammatory cytokine Interleukin-6 (IL-6), with reported IC₅₀ values of 65 µM and 54 µM, respectively.[2]

The inhibition of iNOS and IL-6 formation, along with effects on PMN leukocyte migration, suggests that lornoxicam's anti-inflammatory actions might be broader than just prostaglandin synthesis inhibition. These additional effects could contribute to its overall efficacy, particularly in complex inflammatory states, even if these effects occur at higher concentrations than those required for COX inhibition.

Comparative Potency

In vitro, lornoxicam has been reported to be approximately 100-fold more potent than tenoxicam in inhibiting prostaglandin D₂ (PGD₂) formation in rat polymorphonuclear leukocytes.[10] Clinical comparisons also indicate high efficacy relative to other NSAIDs and even some opioid analgesics in specific pain models.

4. Pharmacokinetics (ADME)

The pharmacokinetic profile of lornoxicam, encompassing its absorption, distribution, metabolism, and excretion (ADME), is crucial for understanding its clinical use, dosing regimens, and potential for variability in patient response.

Absorption

Lornoxicam is characterized by rapid and nearly complete absorption from the gastrointestinal tract following oral administration.

• Bioavailability: The oral bioavailability of lornoxicam is high, reported to be in the range of 90-100%.[4]
• Time to Peak Plasma Concentration (T_max): After oral administration, peak plasma concentrations (C_max) are typically achieved within 1 to 2 hours [39] or up to 2.5 hours.[26] For instance, a 4 mg oral dose of lornoxicam results in a C_max of 280 µg/L within approximately 2.5 hours.[26] Intramuscular injection leads to a more rapid attainment of C_max, generally within 20-25 minutes [26], with an absolute bioavailability of 97% via this route.[26]
• Effect of Food: The presence of food in the stomach can influence the absorption of lornoxicam. Concurrent food intake typically delays the rate of absorption, increasing T_max from approximately 1.5 hours to 2.3 hours, and may slightly reduce the extent of absorption, with the area under the plasma concentration-time curve (AUC) potentially decreasing by approximately 15-20%.[26]
• First-Pass Metabolism: Lornoxicam does not appear to undergo significant first-pass hepatic metabolism.[39] The rapid absorption and high bioavailability contribute significantly to lornoxicam's utility, particularly in acute pain scenarios where a quick onset of action is desired. The food effect suggests that for the most rapid onset, administration on an empty stomach may be preferable.

Distribution

Once absorbed, lornoxicam distributes within the body as follows:

• Plasma Protein Binding: Lornoxicam is highly bound to plasma proteins, with approximately 99% of the drug bound, almost exclusively to serum albumin.[1] This high degree of protein binding can have implications for drug interactions (e.g., displacement by or of other highly bound drugs) and influences the concentration of free, pharmacologically active drug.
• Volume of Distribution (V_d): The apparent volume of distribution of lornoxicam is low, reported as 0.14 L/kg [40] or 0.3 L/kg [26], consistent with its high protein binding restricting extensive tissue distribution.
• Synovial Fluid Penetration: Despite its high protein binding, lornoxicam has been shown to achieve substantial concentrations in synovial fluid.[22] This is clinically relevant as synovial fluid is the proposed site of action for NSAIDs in the treatment of inflammatory joint diseases like osteoarthritis and rheumatoid arthritis.

Metabolism

Lornoxicam undergoes extensive and complete metabolism, primarily in the liver.[4]

• Primary Metabolic Pathway and Enzyme: The principal metabolic pathway for lornoxicam is 5'-hydroxylation, which is predominantly catalyzed by the cytochrome P450 isoenzyme CYP2C9.[4] This specific metabolic route accounts for as much as 95% of the total intrinsic clearance of lornoxicam.[25]
• Major Metabolite: The primary product of this hydroxylation is 5'-hydroxy-lornoxicam, which is pharmacologically inactive.[4]
• Impact of CYP2C9 Genetic Polymorphisms: The pharmacokinetics of lornoxicam are subject to significant interindividual variability, largely attributable to genetic polymorphisms in the CYP2C9 gene.[25]
• Individuals carrying variant alleles such as CYP2C9*2 and CYP2C9*3 (which have reduced catalytic activity) exhibit impaired oral clearance and consequently increased systemic exposure to lornoxicam. For example, studies have shown that individuals heterozygous for the CYP2C9*1 allele (e.g., CYP2C9*1/*3 genotype) can have approximately a 2-fold increase in AUC and a 55% reduction in clearance compared to individuals homozygous for the wild-type CYP2C9*1/*1 allele.[25]
• In rare instances, individuals who are very poor metabolizers of CYP2C9 substrates (e.g., those homozygous or compound heterozygous for deficient alleles) can experience a dramatic prolongation of lornoxicam's elimination half-life (e.g., from the typical 3-5 hours to over 100 hours) and a substantial increase in overall drug exposure, heightening the risk of adverse effects.[25] The heavy reliance on CYP2C9 for metabolism means that individuals with reduced CYP2C9 activity will experience significantly prolonged half-life and increased exposure, potentially negating the safety advantage of the short half-life and increasing the risk of dose-dependent adverse effects.
• Furthermore, physiologically based pharmacokinetic (PBPK) modeling studies suggest that liver cirrhosis can also significantly increase lornoxicam exposure, with the impact potentially being more pronounced than that of CYP2C9 genotype alone, depending on the severity of the liver impairment.[41] The profound influence of CYP2C9 genetic status on lornoxicam's pharmacokinetics underscores the potential for marked differences in drug response and tolerability among patients. This variability suggests that a standard dosing regimen may not be optimal for all individuals, pointing towards the potential clinical utility of pharmacogenetic testing or more cautious dose titration, particularly in populations with a known high prevalence of CYP2C9 variants or in patients who exhibit an unexpected response or adverse effects.

Excretion

Lornoxicam is eliminated from the body primarily in the form of its metabolites.

• Only negligible amounts of the parent drug are excreted unchanged in the urine.[4]
• The elimination routes are both hepatic and renal. Approximately two-thirds of the administered dose (reported as 50-51%) are eliminated via the liver (with metabolites excreted in the faeces through biliary pathways), and about one-third (reported as 42%) is excreted via the kidneys, mainly as 5'-hydroxy-lornoxicam and its glucuronide conjugate.[4]
• The metabolites of lornoxicam do not appear to undergo significant enterohepatic recirculation.[22]

Elimination Half-Life (t_1/2)

A key pharmacokinetic feature of lornoxicam is its relatively short elimination half-life.

• Parent Drug: In individuals with normal CYP2C9 function, the elimination half-life of lornoxicam typically ranges from 3 to 5 hours.[3] This characteristic contributes to its suitability for acute pain management, allowing for a relatively rapid onset of action and potentially reducing the risk of accumulation-related side effects often seen with longer-acting NSAIDs. However, this benefit can be significantly compromised in individuals who are poor metabolizers via CYP2C9.
• Metabolite: The inactive 5'-hydroxy-lornoxicam metabolite has a longer elimination half-life, reported to be approximately 9 to 11 hours.[22]

The pharmacokinetic profile, especially the rapid absorption and short elimination half-life, underpins lornoxicam's clinical utility for acute pain. However, the substantial interindividual variability due to CYP2C9 polymorphisms necessitates careful consideration in clinical practice. For optimal and safe use, particularly in the context of chronic conditions or in patients with potential risk factors, an understanding of an individual's metabolic capacity for lornoxicam could be highly beneficial, aligning with the broader principles of personalized medicine.

Table 2: Key Pharmacokinetic Parameters of Lornoxicam

Parameter	Value	Reference(s)
Bioavailability (Oral)	90-100%	4
Bioavailability (IM)	97%	26
T<sub>max</sub> (Oral, fasted)	1-2.5 hours	26
T<sub>max</sub> (Oral, with food)	~2.3 hours (delayed)	26
T<sub>max</sub> (IM)	~20-25 minutes	26
C<sub>max</sub> (Oral, with food)	Reduced (AUC decreased by ~15-20%)	26
Volume of Distribution (V<sub>d</sub>)	0.14 - 0.3 L/kg	26
Plasma Protein Binding	99% (primarily to albumin)	1
Elimination Half-life (Lornoxicam)	3-5 hours (normal metabolizers)	4
Elimination Half-life (5'-OH-Lornoxicam)	~9-11 hours	22
Primary Metabolic Pathway	5'-Hydroxylation	4
Key Metabolizing Enzyme	CYP2C9	4
Major Metabolite	5'-hydroxy-lornoxicam (inactive)	4
Routes of Excretion	~67% Hepatic (faeces), ~33% Renal (urine, as metabolites)	4
Impact of CYP2C9 Polymorphisms	Significant variability; poor metabolizers show markedly increased t<sub>1/2</sub> and AUC	25

5. Therapeutic Indications and Clinical Efficacy

Lornoxicam is indicated for a range of painful and inflammatory conditions, leveraging its potent analgesic and anti-inflammatory properties.

Approved and Common Indications

The primary therapeutic uses of lornoxicam include:

• Treatment of acute mild to moderate pain: This is a broad indication covering various pain types.[1]
• Symptomatic relief of pain and inflammation in osteoarthritis: Lornoxicam is used to manage the chronic pain and inflammation associated with this degenerative joint disease.[1]
• Symptomatic relief of pain and inflammation in rheumatoid arthritis: It is also employed in the management of this autoimmune inflammatory arthritis.[1]
• Pain associated with sciatica, acute lumbar-sciatica conditions, and low back pain: These musculoskeletal conditions are common targets for lornoxicam therapy.[1]
• Postoperative pain management: Lornoxicam is widely used for pain relief after various surgical procedures, including oral/dental surgery [12], gynaecological surgery, and orthopaedic surgery.[2]
• Ankylosing spondylitis: This chronic inflammatory disease affecting the spine is another indication for lornoxicam.[6]

Summary of Clinical Efficacy

Clinical trials have demonstrated the efficacy of lornoxicam across its indicated uses:

• Postoperative Pain:
• Lornoxicam, particularly at doses of 8 mg or higher, has shown efficacy comparable to or greater than other NSAIDs and even some opioid analgesics in the context of postoperative pain. For instance, after oral surgery, it was found to be at least as effective as comparative NSAIDs and more effective than 10 mg of morphine.[23]
• Oral doses of lornoxicam ranging from 16-24 mg daily were reported to be more effective than 300 mg of tramadol daily for pain management following knee surgery.[23]
• In studies focusing on dental pain (e.g., after third molar extraction), a single oral dose of lornoxicam 8 mg yielded a Number Needed to Treat (NNT) for at least 50% pain relief over 6 hours of 2.9 (95% CI 2.3 to 4.0). This level of efficacy is comparable to that of ibuprofen 200 mg.[13]
• Intramuscular administration of lornoxicam at doses greater than 8 mg was found to be at least as effective as 20 mg of intramuscular morphine.[10]
• A study on pain following third molar surgery demonstrated that lornoxicam treatment resulted in significantly lower median pain scores at 2 hours and 6 hours post-surgery compared to both flurbiprofen and placebo.[42] The consistent demonstration of efficacy in acute pain settings, particularly its performance against established analgesics like opioids and other NSAIDs, suggests a strong analgesic component to lornoxicam's action, possibly extending beyond peripheral anti-inflammatory effects. The NNT of 2.9 for an 8 mg dose in acute dental pain is indicative of robust efficacy. The potential for central analgesic effects, possibly mediated via endorphins as suggested by some preclinical data [10], could contribute to this pronounced analgesia in acute conditions, positioning lornoxicam as a valuable agent where rapid and potent pain relief is paramount, and potentially as an opioid-sparing alternative.
• Osteoarthritis and Rheumatoid Arthritis:
• In patients with osteoarthritis, lornoxicam administered at 4 mg three times daily (tid) or 8 mg twice daily (bid) was found to be as effective as diclofenac 50 mg tid.[17]
• A study in patients with activated osteoarthritis showed that lornoxicam provided significantly superior improvements in pain on movement, pain at rest, nocturnal pain, and duration of morning stiffness when compared to the selective COX-2 inhibitor rofecoxib.[18]
• For long-term management of rheumatoid arthritis, lornoxicam at doses of 8-16 mg/day demonstrated good safety and therapeutic activity, effectively controlling disease progression.[15]
• In another rheumatoid arthritis trial, lornoxicam 8 mg and 16 mg/day showed good therapeutic activity, comparable to diclofenac 150 mg/day. The 16 mg/day dose of lornoxicam was associated with a more pronounced action and better tolerability than diclofenac.[16] A clear dose-response relationship for analgesic efficacy has been observed, particularly in postoperative pain studies. Doses of 8mg and higher generally exhibit superior pain relief compared to lower doses or even some active comparators.[10] For example, one study directly investigating dose-effect relationships for single doses ranging from 4 mg to 32 mg found that 16 mg and 32 mg doses were superior to a 4 mg dose

Works cited

1. Lornoxicam | C13H10ClN3O4S2 | CID 54690031 - PubChem, accessed May 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/54690031
2. PRODUCT INFORMATION - Cayman Chemical, accessed May 16, 2025, https://cdn.caymanchem.com/cdn/insert/70220.pdf
3. What is Lornoxicam used for? - PatSnap Synapse, accessed May 16, 2025, https://synapse.patsnap.com/article/what-is-lornoxicam-used-for
4. Lornoxicam: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 16, 2025, https://go.drugbank.com/drugs/DB06725
5. Lornoxicam | COX | Endogenous Metabolite | TargetMol, accessed May 16, 2025, https://www.targetmol.com/compound/lornoxicam
6. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/8706598/
7. Lornoxicam - Chem-Impex, accessed May 16, 2025, https://www.chemimpex.com/products/37997
8. Lornoxicam - OEL Fastrac with ADE - Affygility Solutions, accessed May 16, 2025, https://affygility.com/oel/lornoxicam.html
9. Lornoxicam = 98 HPLC 70374-39-9 - Sigma-Aldrich, accessed May 16, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml0338
10. LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES, accessed May 16, 2025, https://jddtonline.info/index.php/jddt/article/download/403/267/1453
11. LORNOXICAM - New Drug Approvals, accessed May 16, 2025, https://newdrugapprovals.org/2021/10/22/lornoxicam/
12. EP2394641A1 - Pharmaceutical formulations of lornoxicam - Google ..., accessed May 16, 2025, https://patents.google.com/patent/EP2394641A1/en
13. Single dose oral lornoxicam for acute postoperative pain in adults - PMC - PubMed Central, accessed May 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6485324/
14. Single dose oral lornoxicam for acute postoperative pain in adults - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/19821419/
15. [Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis] - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/12207202/
16. [Analgesic dose range finding of lornoxicam compared to diclofenac. Crossover double blind study in rheumatoid arthritis] - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/12404032/
17. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/8877932/
18. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study) - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/17516707/
19. Xefo - referral | European Medicines Agency (EMA), accessed May 16, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/xefo
20. XEFO - Biolab, accessed May 16, 2025, https://www.biolabfarma.com.br/en/product-9/xefo-2/
21. Lornoxicam Tablets - Neutral Pharma, accessed May 16, 2025, https://neutralpharma.com/product/lornoxicam-tablets/
22. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. | DrugBank Online, accessed May 16, 2025, https://go.drugbank.com/articles/A7025
23. Lornoxicam, a new potent NSAID with an improved tolerability profile. | DrugBank Online, accessed May 16, 2025, https://go.drugbank.com/articles/A7024
24. Lornoxicam, a new potent NSAID with an improved tolerability profile - ResearchGate, accessed May 16, 2025, https://www.researchgate.net/publication/10646518_Lornoxicam_a_new_potent_NSAID_with_an_improved_tolerability_profile
25. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 ..., accessed May 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1884973/
26. LORNOXICAM: A REVIEW OF ITS THERAPEUTIC POTENTIAL IN DIFFERENT CLINICAL STUDIES, accessed May 16, 2025, https://jddtonline.info/index.php/jddt/article/download/403/267
27. Piroxicam - Wikipedia, accessed May 16, 2025, https://en.wikipedia.org/wiki/Piroxicam
28. FDA-Approved Lornoxicam API Manufacturers & Suppliers - Pharmaoffer.com, accessed May 16, 2025, https://pharmaoffer.com/api-excipient-supplier/nsaids/lornoxicam/fda
29. Lornoxicam (International database) - Drugs.com, accessed May 16, 2025, https://www.drugs.com/international/lornoxicam.html
30. Lornoxicam | CAS 70374-39-9 | SCBT - Santa Cruz Biotechnology, accessed May 16, 2025, https://www.scbt.com/p/lornoxicam-70374-39-9
31. Lornoxicam (Chlortenoxicam, Ro 13-9297, CAS Number: 70374-39-9) | Cayman Chemical, accessed May 16, 2025, https://www.caymanchem.com/product/70220/lornoxicam
32. Lornoxicam, accessed May 16, 2025, https://www.drugfuture.com/chemdata/lornoxicam.html
33. pubchem.ncbi.nlm.nih.gov, accessed May 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/54690031#:~:text=Lornoxicam%20is%20a%20thienothiazine%2Dderived,amino%20group%20of%202%2Daminopyridine.
34. Lornoxicam Eight Chongqing Chemdad Co. ，Ltd, accessed May 16, 2025, https://chemdad.com/index.php?c=article&id=59935
35. Lornoxicam - Wikipedia, accessed May 16, 2025, https://en.wikipedia.org/wiki/Lornoxicam
36. What is the mechanism of Lornoxicam? - Patsnap Synapse, accessed May 16, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-lornoxicam
37. acinoedudoc.com, accessed May 16, 2025, https://acinoedudoc.com/wp-content/uploads/2023/11/Xefo-Rapid-pi.pdf
38. Tolerability of the COX-1/COX-2 Inhibitor Lornoxicam in the Treatment of Acute and Rheumatic Pain, accessed May 16, 2025, https://www.tandfonline.com/doi/pdf/10.2217/pmt.16.7
39. Spedicam.pdf - PharmEvo, accessed May 16, 2025, https://pharmevo.biz/wp-content/uploads/2021/03/Spedicam.pdf
40. lornoxicam - Drug Central, accessed May 16, 2025, https://drugcentral.org/drugcard/1609
41. Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis | Request PDF - ResearchGate, accessed May 16, 2025, https://www.researchgate.net/publication/363184442_Physiologically_based_pharmacokinetic_PBPK_modeling_of_lornoxicam_Exploration_of_doses_for_CYP2C9_genotypes_and_patients_with_cirrhosis
42. Analysis of the Effectiveness of Lornoxicam and Flurbiprofen on Management of Pain and Sequelae Following Third Molar Surgery: A Randomized, Controlled, Clinical Trial - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/30866586/
43. Analysis of the Effectiveness of Lornoxicam and Flurbiprofen on Management of Pain and Sequelae Following Third Molar Surgery: A Randomized, Controlled, Clinical Trial - PubMed Central, accessed May 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6463050/
44. www.efda.gov.et, accessed May 16, 2025, https://www.efda.gov.et/wp-content/uploads/2024/02/Lornoxicam-8-mg-fim-coated-tablet_ZENORIT_Tabuk-Pharmaceuticals-Manufacturing-Company.pdf
45. Lornoxicam - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed May 16, 2025, https://www.practo.com/medicine-info/lornoxicam-172-api
46. Lornoxicam: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed May 16, 2025, https://www.apollopharmacy.in/salt/Lornoxicam
47. Pharmacovigilance analysis of small bowel bleeding associated with NSAIDs, accessed May 16, 2025, https://www.researchgate.net/publication/391486547_Pharmacovigilance_analysis_of_small_bowel_bleeding_associated_with_NSAIDs
48. Lornoxicam | Uses, Side Effects & Medicines - Truemeds, accessed May 16, 2025, https://www.truemeds.in/drug-salts/lornoxicam-340
49. Non-steroidal anti-inflammatory drugs and cardiovascular risks in the - GOV.UK, accessed May 16, 2025, https://assets.publishing.service.gov.uk/media/5df7610ee5274a08f518e911/Non-steroidal_anti-inflammatory_drugs__NSAIDs__cardiovascular_risks.pdf
50. Revisions of PRECAUTIONS (FY2024) | Pharmaceuticals and Medical Devices Agency, accessed May 16, 2025, https://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0012.html
51. Japan Drug Approvals | March 2024 | PMDA | MHLW Updates - iPharmaCenter, accessed May 16, 2025, https://www.ipharmacenter.com/post/japan-drug-approvals-march-2024-pmda-mhlw-updates-ipharmacenter
52. lornoxicam - PharmGKB, accessed May 16, 2025, https://www.pharmgkb.org/chemical/PA165958395
53. Questions and answers: Article 30 referral procedures | European Medicines Agency (EMA), accessed May 16, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/questions-answers-article-30-referral-procedures
54. Information for marketing authorisation holder - SÚKL, accessed May 16, 2025, https://sukl.gov.cz/en/referrals/information-for-marketing-authorisation-holder-3/
55. Review decisions - Drug and Health Products Portal, accessed May 16, 2025, https://dhpp.hpfb-dgpsa.ca/review-documents
56. Rizatriptan: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 16, 2025, https://go.drugbank.com/drugs/DB00953
57. Australian Register of Therapeutic Goods (ARTG), accessed May 16, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
58. Safety review: Nonsteroidal anti-inflammatory drugs (NSAIDs) and spontaneous abortion - Therapeutic Goods Administration (TGA), accessed May 16, 2025, https://www.tga.gov.au/sites/default/files/safety-review-nonsteroidal-anti-inflammatory-drugs-nsaids-and-spontaneous-abortion.docx
59. Differentiating Oxicam Nonsteroidal Anti-Inflammatory Drugs in Phosphoglyceride Monolayers | Request PDF - ResearchGate, accessed May 16, 2025, https://www.researchgate.net/publication/40765839_Differentiating_Oxicam_Nonsteroidal_Anti-Inflammatory_Drugs_in_Phosphoglyceride_Monolayers
60. Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/11846620/
61. Efficacy and safety of lornoxicam vs ibuprofen in primary dysmenorrhea: a randomized, double-blind, double dummy, active-controlled, cross over study - PubMed, accessed May 16, 2025, https://pubmed.ncbi.nlm.nih.gov/25808572/